We have developed a highly-versatile therapeutic antibody capable of deployment in various therapeutic modalities such as antibody-drug conjugate, chimeric antigen receptor and bi/tri-functional biologics.

Our Biologics developmental pipeline is geared towards creating novel single chain polypeptide molecules that link the single chain variable fragment of the LGR5 antibody to moieties that both bind to and activate cytotoxic immune cells. We also include other moieties that modulate the potency and persitence of immune cell cytotoxicity.